Healthcare Global Enterprises Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹732 Cr +13.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
HG

Healthcare Global Enterprises Ltd

Q4 FY26Healthcare Services

Healthcare Global Enterprises Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹652Cr
+11.5% YoY
+3% QoQ
Net profit
₹4Cr
−40.3% YoY
Turned profitable QoQ
Margin
19.17%
+1.1 pp YoY
+1.9 pp QoQ
Price₹726
Market cap₹10.7K Cr
P/E221.4

The short version

FY26 revenue growth was 15% year-on-year, with broad-based growth across regions. HCG targets around 15% revenue growth over the medium term, supported by 12% patient volume growth and 3% improvement in average revenue per patient (ARPP).

From Healthcare Global Enterprises Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY26 revenue growth was 15% year-on-year, with broad-based growth across regions.
  • Q4 growth impacted by paring down low-margin business and Middle East conflict affecting medical value travel; normalization expected in coming quarters.
  • Medium-term revenue growth estimate remains close to 15%.
  • Patient volumes increased by 12% with a 3% improvement in average revenue per patient.
  • Growth driven by better center utilization, clinical talent additions (23 oncologists added in Q4), and expansion initiatives like North Bangalore and Whitefield.
  • Expansion via brownfield projects (adding 200+ beds over 24 months in multiple cities) and selective greenfield projects in 10-12 cities under evaluation.
  • Digital and sales acceleration efforts (doubling Day-Care centers) to support growth.

2 more points from Healthcare Global Enterprises Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Healthcare Global Enterprises Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Near-term capex focused on brownfield expansions with faster ramp-up and better returns.
  • Approximately 200+ beds to be added over the next 24 months: 75 in Cuttack, 30 in Ranchi, 50 in Vizag, 20+ in Bhavnagar.
  • Selective greenfield expansions planned, including North Bangalore and Whitefield facilities; evaluation ongoing for 10-12 additional cities (e.g., Pune, Surat, Coimbatore, Nellore, Lucknow, Jalandhar).
  • Average brownfield bed addition cost estimated at INR 45 lakh per bed; INR 90-100 crore CAPEX for 200 beds.
  • Capital raised INR 425 crore rights issue strengthens financial foundation for capacity expansion, clinical infrastructure upgrades, and technology investments.
  • Asset-light model adopted for new technology like MR-Linac on a pay-per-use basis.

2 more points from Healthcare Global Enterprises Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Healthcare Global Enterprises Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The discussion primarily focuses on operational performance, expansion plans, financial results, margins, growth strategies, and new facilities such as the North Bangalore facility with the MR-Linac. No references to order book status or pending orders are made in the transcript.

Healthcare Global Enterprises Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Healthcare Global Enterprises Ltd Q4 FY26 results — key figures

Healthcare Global Enterprises Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue652585+11.5%633+3%
Operating profit (EBITDA)125106+18.4%110+14.2%
Operating margin19.17%18.05%+1.1 pp17.31%+1.9 pp
Profit before tax114-90.8%-6—
Net profit (PAT)47-40.3%-8—
EPS (₹)0.150.52-71.2%-0.66—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹732 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Suven Life Sciences (Q4 FY26)

    The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

  • Invicta Diagnostic (Q4 FY26)

    Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…

  • KMC Speciality (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • Star Imaging (Q4 FY26)

    Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Healthcare Global Enterprises Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Healthcare Global Enterprises Ltd Q4 FY26 results?

FY26 revenue growth was 15% year-on-year, with broad-based growth across regions. HCG targets around 15% revenue growth over the medium term, supported by 12% patient volume growth and 3% improvement in average revenue per patient (ARPP).

What is Healthcare Global Enterprises Ltd share price analysis?

Healthcare Global Enterprises Ltd currently shows a neutral. The stock trades at a P/E of 221.3 with a market cap of ₹10,665 Cr. Investors should review the full earnings analysis for detailed insights.

Is Healthcare Global Enterprises Ltd planning capital expenditure?

Near-term capex focused on brownfield expansions with faster ramp-up and better returns.

Keep Healthcare Global Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.